Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Heart failure. Current pharmacologic treatment].

I Coma-Canella1, S Castaño, E Nasarre

  • 1Departamento de Cardiologia y Cirugia Cardiovascular, Clínica Universitaria, Facultad de Medicina, Universidad de Navarra, Pamplona. icoma@unav.es

Revista De Medicina De La Universidad De Navarra
|January 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prediction of the potential biological activity of novel spiropyrazolo[3,4-b]pyridines and spiropyrazolo[3,4-b]pyridine-5,5'-pyrimidines by a ligand-protein inverse-docking approach.

Journal of molecular graphics & modelling·2020
Same author

Faecal contamination in public pools in Barcelona province: Cryptosporidium spp. and bacterial indicators.

Journal of water and health·2018
Same author

Could stress magnetic resonance imaging be useful in patients with a low probability of ischemic heart disease?

Radiologia·2018
Same author

[Patients with vulnerable coronary plaques have higher serum metalloproteinase-1 levels].

Anales del sistema sanitario de Navarra·2017
Same author

Structure and interaction with lipid membrane models of Semliki Forest virus fusion peptide.

Biochimica et biophysica acta·2016
Same author

Denitrification in a hypersaline lake-aquifer system (Pétrola Basin, Central Spain): the role of recent organic matter and Cretaceous organic rich sediments.

The Science of the total environment·2014
Same journal

[The interests of the medical class].

Revista de medicina de la Universidad de Navarra·2009
Same journal

[Treatment to conserve fertility in a patient diagnosed with deep pelvic endometriosis].

Revista de medicina de la Universidad de Navarra·2009
Same journal

[Treatment for endometriosis].

Revista de medicina de la Universidad de Navarra·2009
Same journal

[Basic research into endometriosis. Are we going in the right direction?].

Revista de medicina de la Universidad de Navarra·2009
Same journal

[Diagnosis of endometriosis].

Revista de medicina de la Universidad de Navarra·2009
Same journal

Ultrasound study of the myoendometrial border.

Revista de medicina de la Universidad de Navarra·2009
See all related articles

Effective heart failure (HF) management combines multiple drug classes to improve symptoms and reduce mortality. Adding angiotensin-converting enzyme inhibitors, beta-blockers, and aldosterone antagonists significantly lowers mortality rates in HF patients.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Heart failure (HF) treatment has evolved significantly, focusing on symptom improvement and preventing disease progression.
  • Current therapeutic strategies aim to prevent the transition from asymptomatic systolic dysfunction to symptomatic HF, mitigate cardiac remodeling and renal dysfunction, and reduce overall mortality.

Purpose:

  • To review the current pharmacological approaches for heart failure management.
  • To highlight the additive benefits of combining different drug classes in HF treatment.
  • To discuss the role of specific drug families, including newer agents like Levosimendan for acute HF.

Summary:

  • Key drug classes for HF include cardiac glycosides, diuretics, ACE inhibitors (ACEI), beta-blockers (BB), angiotensin-II receptor blockers (ARB), and aldosterone receptor antagonists.

Related Experiment Videos

  • Combination therapy with ACEI, BB, and aldosterone antagonists demonstrates additive benefits, progressively reducing two-year mortality from 34% to 10% in mild to moderate HF.
  • While new positive inotropic drugs have not been approved for chronic HF due to increased mortality, Levosimendan shows promise in acute settings.

    • Impact:

    • Optimized drug combinations can significantly improve patient prognosis and reduce mortality in heart failure.
    • Understanding the additive effects of various drug classes allows for tailored treatment strategies to manage HF effectively.
    • The review underscores the importance of evidence-based pharmacological interventions in managing the complexities of heart failure.